AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01259024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization using a drug-eluting bead
Description: Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
Study NCT01104298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
Study NCT01104298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
Study NCT00564070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual plus adherence training
Description: The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.
Study NCT00564070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced treatment as usual plus CBT-AD
Description: The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
Study NCT03522259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 10 MG Oral Tablet [Xarelto]
Description: Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)
Study NCT01169259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.
Study NCT04275479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose Tolerance Test
Description: This is a two step process. Subjects will be asked to fast overnight,(no food and only water to drink for at least 8 hours). Then when subjects arrive for the visit,participants will have blood drawn and be asked to drink a sugary liquid. One hour later, another blood sample will be drawn and after two hours a final blood sample will be drawn.
Study NCT04275479 — intervention group
Intervention type: OTHER
Intervention: Modified Oral Glucose Tolerance Test
Description: The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). There will be no blood drawn during this test, participant will be asked to drink a sugary liquid and to remaining fasting (water only) for the two hour after finishing the drink.
Study NCT04275479 — intervention group
Intervention type: OTHER
Intervention: Modified Mixed Meal Tolerance Test
Description: The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). The participant will be given a meal supplement to drink in place of breakfast, for example Boost Plus. The participant will be asked to drink the meal supplement and to remaining fasting (water only) for the next two hours.
Study NCT04275479 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Monitor
Description: The participant will be provided a CGM device to wear for 10 days during the study period. The CGM will be blinded (meaning that the participant will not be able to see the results).
Study NCT04275479 — intervention group
Intervention type: OTHER
Intervention: Food Diary
Description: The participant will be asked to maintain a detailed food diary for 3 days during the 10 day study period.
Study NCT04275479 — intervention group
Intervention type: OTHER
Intervention: Medical History Questionnaires
Description: The participant will be asked to provide detailed medical history
Study NCT00835575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg (Orally Disintegrating) Tablets
Description: 1 x 15 mg, single-dose fasting
Study NCT00835575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REMERON SolTab® 15 mg Orally Disintegrating Tablets
Description: 1 x 15 mg, single-dose fasting
Study NCT00302146 — intervention group
Intervention type: DRUG
Intervention: 15-0 H20
Study NCT00663663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Delivered Intervention 1
Description: Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
Study NCT00663663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Delivered Intervention 2
Description: Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
Study NCT00137254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: IV insulin
Study NCT00137254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stable Isotopes
Description: IV administration of stable isotopes
Study NCT00137254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: IV administration of ICG
Study NCT00840398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BUSPAR® 30 mg Tablet
Description: 1 x 30 mg, single-dose fed
Study NCT00840398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone Hydrochloride 30 mg Tablet
Description: 1 x 30 mg, single-dose fed
Study NCT00151229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: target blood pressure
Study NCT02203760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib plus Gemcitabine
Description: Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
Study NCT01683045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Estech COBRA® Surgical System
Description: The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
Study NCT01342939 — intervention group
Intervention type: OTHER
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: 50g waterfree glucose dissolved in 300ml water consumed over 5 min.
Study NCT02203760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Pazopanib 800 mg orally once daily
Study NCT01342939 — intervention group
Intervention type: OTHER
Intervention: iso glycaemic intravenous (iv) glucose infusion (IIGI)
Description: 20% glucose
Study NCT01342939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Meal test
Description: Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
Study NCT01342939 — intervention group
Intervention type: OTHER
Intervention: Sitagliptin
Description: Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
Study NCT01342939 — intervention group
Intervention type: OTHER
Intervention: Incretin effect on sulphonyl urea treatment
Description: Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
Study NCT04684186 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular fiducial marker insertion
Description: Fiducial markers will be inserted using an endovascular route
Study NCT04684186 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopic fiducial marker insertion
Description: Fiducial markers will be inserted using an endoscopic route
Study NCT02280863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Hybrid Closed-loop System - Android Platform
Description: A continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm using an Android controller.
Study NCT02280863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Hybrid Closed-loop Integrated System
Description: A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm
Study NCT01326494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1 Oral Cortico Steroids
Description: Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.~Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )
Study NCT03461380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Menopause Relief EP-40
Description: Fixed combination of black cohosh and Rhodiola rosea
Study NCT03461380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Black Cohosh
Description: 6.5 mg black cohosh
Study NCT03461380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Black Cohosh
Description: 500 mg black cohosh
Study NCT03461380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 600 mg excipient
Study NCT00581607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: drug given for 16 weeks
Study NCT00581607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01327781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxifen Hydrochloride
Description: Given PO
Study NCT01327781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01327781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01383122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed electromagnetic field device (ActiPatch TM)
Description: Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
Study NCT01383122 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive pulsed electromagnetic field device (ActiPatch TM)
Description: Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
Study NCT02367612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented milk
Description: Fermented milk with Lactobacillus paracasei CBA L74
Study NCT02367612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT02263365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
Study NCT02435628 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: All subjects will complete baseline psychological assessments prior to their medical visit. Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
Study NCT03078517 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: After the induction of anesthesia, i-gel is inserted along the palatopharyngeal curve.
Study NCT01327781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02492919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medixair®
Description: Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
Study NCT02974426 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PORT-first
Description: PORT administered at the first day of adjuvant therapy, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
Study NCT02974426 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PORT-last
Description: PORT administered sequentially after participants received adjuvant chemotherapy for four cycles, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
Study NCT02974426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
Description: Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
Study NCT02974426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
Description: Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
Study NCT02717715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home base stroke rehabilitation
Description: The intervention consists of physiotherapy exercises targeting functional and physical capacity.
Study NCT03307070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for individuals with TBI
Description: Cognitive Behavioral Therapy for depression that has been adapted for a population who has experienced a moderate to severe Traumatic Brain Injury. This is a 12 week long treatment for depression with weekly visits that challenges negative thoughts and behaviors. This version has been specifically developed for the study to account for specific cognitive needs of individuals who have experienced a moderate to severe TBI.
Study NCT03307070 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Participants will be randomized to a waitlist. They will attend biweekly study sessions for 12 weeks to track progress, but will receive their treatment as usual.
Study NCT01362270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum Acupuncture
Description: DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
Study NCT01362270 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
Study NCT02247856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony
Study NCT02247856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony
Study NCT02247856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebulizer
Description: Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min
Study NCT02247856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebulizer (VMN)
Description: Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
Study NCT04163770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: caliberation of pacemaker
Description: evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
Study NCT02802085 — intervention group
Intervention type: DEVICE
Intervention: VEGA Knee
Description: TKA
Study NCT03078517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway protector
Description: After the inudction of anesthesia, laryngeal mask airway protector is inserted along the palatopharyngeal curve, and the cuff is inflated.
Study NCT02514070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA-rich fish oil
Description: 4 gel capsules, 3 times/day for 6 weeks
Study NCT02514070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil
Description: 4 gel capsules, 3 times/day for 6 weeks
Study NCT02046200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.
Study NCT02046200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT00041015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT02046200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Study NCT02046200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Study NCT00041015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Study NCT00041015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00153166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin and pioglitazone
Description: atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
Study NCT00153166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin and pioglitazone
Description: atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
Study NCT00153166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin/placebo
Description: atorvastatin 80 mg orally once daily and matching placebo orally twice daily
Study NCT00507507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
Study NCT00507507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC
Description: Emtricitabine (FTC) 200 mg capsule taken orally once daily
Study NCT00507507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match FTC taken once daily
Study NCT02326090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cis-UCA ophthalmic solution 1.0%
Study NCT02326090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cis-UCA ophthalmic solution 2.5%
Study NCT02326090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Study NCT02560792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Condition
Description: Participants read: Most people exercising at this intensity say that it feels good, and that it makes them feel energized and more positive, and more relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to positive feelings, and what specifically about this exercise might make you, personally, feel good.